Roche’s earnings hit by Genentech acquisition

Thursday 4 February 2010

The Roche group’s net income declined by 22% to CHF 8.5 billion in 2009 as it absorbed the cost of acquiring and integrating Genentech. Group sales, however, rose by 8% and the company proposed a 20% increase in its dividend.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

See map: Google Maps